Discover
CLRB
Cellectar Biosciences, Inc.
2.83
2 x 2.03
2 x 3.46
bid
ask
+
0.05
1.80%
2 @ 04:00 PM
2.60 -0.23 (8.13%)
| Ytd | -4.07% | |
| 1y | -41.77% |
2.70
day range
2.89
2.20
52 week range
6.52
| Open | 2.79 | Prev Close | 2.78 | Low | 2.70 | High | 2.89 | Mkt Cap | 22.62M |
| Vol | 92.15K | Avg Vol | 1.05M | EPS | -5.38 | P/E | N/A | Forward P/E | -0.10 |
| Beta | 1.01 | Short Ratio | 8.34 | Inst. Own | 34.55% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.80 | 200-d Avg | 3.37 | 1yr Est | 5.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-18 | 2024-09 | -0.35 | -0.55 | -0.2 | -57.14% |
| 2024-05-14 | 2024-03 | -0.5 | -0.4 | 0.1 | 20.00% |
| 2024-03-27 | 2023-12 | -0.59 | -0.66 | -0.07 | -11.86% |
| 2023-08-14 | 2023-06 | -0.69 | -0.73 | -0.04 | -5.80% |
| 2023-05-04 | 2023-03 | -0.75 | -0.76 | -0.01 | -1.33% |
| 2023-03-09 | 2022-12 | -0.83 | -0.55 | 0.28 | 33.73% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | Oppenheimer | Downgrade | Outperform | Perform |
| 2024-11-19 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-03-28 | Roth MKM | Upgrade | Buy | Buy |
| 2024-03-28 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-03-04 | Roth MKM | Upgrade | Buy | Buy |
| 2022-11-04 | HC Wainwright & Co. | Upgrade | Buy |
Profile
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-12-07 | CARUSO JAMES V | Chief Executive Officer | 49.24K | Stock Award(Grant) |
| 2023-12-07 | KOLEAN CHAD J | Chief Financial Officer | 42.58K | Stock Award(Grant) |
| 2023-12-07 | LEA DARRELL SHANE | Officer | 39.60K | Stock Award(Grant) |
| 2023-12-07 | LONGCOR JARROD | Chief Operating Officer | 53.14K | Stock Award(Grant) |
| 2023-12-07 | SHUSTOV ANDREI | Officer | 55.04K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Rosalind Advisors, Inc. | 3.67M | 1.01M | 8.90% |
| 2024-09-29 | AIGH Capital Management LLC | 3.20M | 881.52K | 7.75% |
| 2024-09-29 | Nantahala Capital Management, LLC | 2.71M | 747.82K | 6.57% |
| 2024-09-29 | Vanguard Group Inc | 1.73M | 476.13K | 4.18% |
| 2024-09-29 | Adar1 Capital Management, LLC | 1.02M | 281.81K | 2.48% |
| 2024-09-29 | Geode Capital Management, LLC | 352.45K | 97.17K | 0.85% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.07M | 295.74K | 2.60% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 568.75K | 156.81K | 1.38% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 179.88K | 49.59K | 0.44% |
| 2024-10-30 | iShares Micro Cap ETF | 81.91K | 22.58K | 0.20% |
| 2024-10-30 | Fidelity Total Market Index Fund | 61.94K | 17.08K | 0.15% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 42.43K | 11.70K | 0.10% |
Split
| Split | Date |
|---|---|
| 1 : 30 | 2025-06-24 |
| 1 : 10 | 2022-07-22 |
| 1 : 10 | 2018-07-17 |
| 1 : 10 | 2016-03-07 |
| 1 : 20 | 2014-06-16 |
| 0.00654 : 1 | 2011-04-11 |